Fate Therapeutics (NASDAQ:FATE) stock rallied 37% Monday after the company reported that the first patient in the Phase 1 ...
48m
Results from a randomized, phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback